Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
about
The history of dopamine and levodopa in the treatment of Parkinson's diseaseCatechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's diseaseInterventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.Pharmacological treatment of Parkinson's disease.Diagnosis and treatment of Parkinson disease: molecules to medicineNeurologist care in Parkinson disease: a utilization, outcomes, and survival study.Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.Drug treatment of Parkinson's diseaseUtility of tolcapone in fluctuating Parkinson's diseaseImproving L-dopa therapy: the development of enzyme inhibitors.Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
P2860
Q22252881-CBFA1444-5B12-4980-A70F-2DED85A4FEFFQ24245911-8BF2DB9C-6FF4-49C7-8450-A72DAD8DDC5DQ33771370-E2F4B95C-1DEE-4B07-BE24-CA26774B6CC6Q34048261-1B8B8019-E83E-43D1-92CE-9E2E707F1A47Q34698876-4C56F2AB-85BE-4A75-8A25-190CFC44D76FQ35183563-13E4BEC8-0850-4FC8-ACA8-4FC3AE0DA146Q36040754-89C673D1-3876-410B-9588-9D210D69BE4EQ36094535-BA0955FE-3AA9-46F9-946E-C79A5C5060FBQ36174698-29FBD73D-DA16-429C-9B7C-5D58BC0AD290Q36902632-2D5107B8-806D-4F19-95FD-0AF502900E7BQ37018938-D1F4DD23-76DA-4929-B6C3-2CB9561AA982Q38261811-618C6D34-8374-4A48-ACF2-AAE529E7D807Q43825521-B83DC723-4D31-4B34-B7BC-33D671371DD5Q43856186-F96A0CD6-EE30-44E9-B751-43E44C62E683Q45075694-28300D17-828D-4565-B949-2CD6173F6F1FQ46116294-6C6C6AEB-DBF0-4A92-8085-99C8530A2A82
P2860
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Catechol-O-methyltransferase i ...... tion in parkinsonian patients.
@en
Catechol-O-methyltransferase i ...... tion in parkinsonian patients.
@nl
type
label
Catechol-O-methyltransferase i ...... tion in parkinsonian patients.
@en
Catechol-O-methyltransferase i ...... tion in parkinsonian patients.
@nl
prefLabel
Catechol-O-methyltransferase i ...... tion in parkinsonian patients.
@en
Catechol-O-methyltransferase i ...... tion in parkinsonian patients.
@nl
P2093
P356
P1433
P1476
Catechol-O-methyltransferase i ...... tion in parkinsonian patients.
@en
P2093
G Cora-Locatelli
J W Roberts
M A Amantea
M M Mouradian
P304
P356
10.1212/WNL.43.12.2685
P407
P577
1993-12-01T00:00:00Z